Multidisciplinary Modalities Achieve Encouraging Long-Term Survival in Resectable Limited-Disease Esophageal Small Cell Carcinoma
Open Access
- 9 July 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7), e69259
- https://doi.org/10.1371/journal.pone.0069259
Abstract
The management of limited-disease esophageal small cell carcinoma is not well defined, and the role of surgery is still controversial. We aim to determine the optimal treatment strategy in limited-disease of esophageal small cell carcinoma. We conducted a retrospective review of 141 patients with limited-disease esophageal small cell carcinoma from 3 institutions in China who underwent treatment between July 1994 and September 2008, July 1994 and July 2011, and June 2004 and December 2010, respectively. The survival rate was calculated by the Kaplan-Meier method, and the log-rank test was used to assess the survival differences between the groups. Cox proportional hazards model were used to further determine the independent factors impacting overall survival. The median survival time was 16.1 months for the entire cohort of patients, with a 5-year survival rate of 6.7%. The median survival times for surgery alone, surgery combined with chemotherapy, surgery combined with radiotherapy, surgery combined with chemotherapy and radiotherapy, chemotherapy plus radiotherapy, and chemotherapy alone were 18.0 months, 15.0 months, 23.0 months, 25.0 months, 17.1 months, and 6.1 months, respectively; the corresponding 5-year survival rates were 0%, 15.4%, 0%, 38.9%, 0%, and 0%, respectively. For the 105 patients who underwent R0 resection, the median disease-free survival time was 12.0 months, with a 95% confidence interval of 9.5 months to 14.5 months. The multivariate Cox regression analysis demonstrated that advanced pathological staging (p = 0.003), and pure esophageal small cell carcinoma (p = 0.035) were independent factors decreasing overall survival. Our data suggested that multidisciplinary modalities achieved encouraging long-term survival in patients with resectable limited-disease of esophageal small cell carcinoma.This publication has 28 references indexed in Scilit:
- Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC?International Journal of Clinical Oncology, 2011
- Small Cell Carcinoma of the Esophagus: A Report of 16 Cases From a Single Institution and Literature ReviewThe Annals of Thoracic Surgery, 2011
- Treatment and prognosis of limited disease primary small cell carcinoma of esophagusDiseases of the Esophagus, 2010
- Original article: Surgical management for small cell carcinoma of the esophagusDiseases of the Esophagus, 2010
- Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 casesDiseases of the Esophagus, 2010
- Should We Recommend Surgery to Patients with Limited Small Cell Carcinoma of the Esophagus?Journal of Thoracic Oncology, 2008
- Clinicopathologic features and histochemical analyses of proliferative activity and angiogenesis in small cell carcinoma of the esophagusThe Esophagus, 2007
- Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experienceAnnals of Oncology, 2007
- Primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of 21 casesBMC Cancer, 2007
- Small Cell Carcinomas of the Gastrointestinal Tract: Clinicopathological Features and Treatment ApproachSeminars in Oncology, 2007